Susan Doleman

Vice President of Clinical Development

Susan Doleman joined Replimune from Epizyme where she was Senior Director, Clinical Operations. From 2006-2015, Susan had increasing responsibility at BioVex/Amgen where she ultimately led clinical operations for the pivotal Phase 3 program with T-VEC until BLA filing. Previously Susan has held clinical operations roles at a number of biotechnology companies including Critical Therapeutics Inc, ToleRX Inc and Genzyme Corp.